KBI Biopharma Executive and Leadership Team

November, 2026

Leadership Overview

KBI Biopharma has 5 executives leading key functions including strategy, operations, finance, human resources, and regional expansion.

Focused on accelerating the delivery of complex biologics to patients worldwide, KBI Biopharma maintains a commitment to scientific excellence and manufacturing precision. This leadership team drives the organization toward sustainable growth and innovation within the global life sciences sector.

Leadership Roles at KBI Biopharma

  • Chief Executive Officer - Lorraine Russ
  • Chief Financial Officer - Katherine Wolf
  • Chief Operating Officer - Peter Carbone
  • President, Kbi Biopharma (Japan) - Toshihiro Ogawa
  • Chief People Officer - Debra Bruneau
  • Lorraine Russ - Chief Executive Officer

    Lorraine Russ, the Chief Executive Officer at KBI Biopharma, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the integration of complex biologics development and manufacturing services, the Chief Executive Officer ensures alignment across all global business units. This leadership role involves fostering partnerships with life sciences companies to accelerate the path from early development to commercial production. By prioritizing scientific innovation and operational excellence, Lorraine Russ drives the company toward market leadership in the contract development and manufacturing space. The Chief Executive Officer maintains a focus on scaling infrastructure to meet the evolving needs of the pharmaceutical industry. Through rigorous oversight of organizational performance, the Chief Executive Officer secures the competitive position of the firm. Ultimately, the Chief Executive Officer champions the mission of delivering life-saving medicines and vaccines to patients through advanced technological capabilities and specialized expertise.

    Katherine Wolf - Chief Financial Officer

    Katherine Wolf, the Chief Financial Officer at KBI Biopharma, directs the financial strategy, capital allocation, and fiscal planning for the organization. Overseeing the financial health of the company, the Chief Financial Officer ensures that resources support the expansion of manufacturing capabilities and the adoption of specialized technologies. This leadership role involves managing investor relations and providing the analytical rigor necessary for long-term business sustainability. By monitoring market trends and financial performance, Katherine Wolf enables the company to invest in critical infrastructure and scientific talent. The Chief Financial Officer collaborates with the executive team to evaluate growth opportunities and mitigate financial risks associated with global operations. Through the maintenance of robust financial controls, the Chief Financial Officer supports the overall mission of accelerating medicine development. Ultimately, the Chief Financial Officer secures the financial foundation required to sustain the competitive advantage of the firm within the global biopharmaceutical market.

    Peter Carbone - Chief Operating Officer

    Peter Carbone, the Chief Operating Officer at KBI Biopharma, manages the execution of global manufacturing operations and process development workflows. Overseeing the technical teams responsible for cell line and analytical characterization, the Chief Operating Officer ensures that all production facilities maintain the highest standards of quality and efficiency. This leadership role involves optimizing the supply chain and manufacturing capacity to support the rapid acceleration of innovative biologics. By streamlining internal processes, Peter Carbone directly impacts the ability of the company to meet clinical and commercial production timelines. The Chief Operating Officer coordinates with cross-functional departments to resolve complex technical challenges during the development lifecycle. Through the implementation of advanced manufacturing technologies, the Chief Operating Officer drives operational excellence across all sites. Ultimately, the Chief Operating Officer guarantees that the organization delivers consistent, high-quality results for clients navigating the complex landscape of modern drug development.

    Toshihiro Ogawa - President, Kbi Biopharma (Japan)

    Toshihiro Ogawa, the President, Kbi Biopharma (Japan) at KBI Biopharma, directs the strategic expansion and operational oversight of the company within the Japanese market. Overseeing regional initiatives, the President, Kbi Biopharma (Japan) ensures that the organization provides localized support for complex biologics development and manufacturing. This leadership role involves building strong relationships with regional life sciences partners and navigating the specific regulatory and market nuances of the area. By leveraging the global expertise of the firm, Toshihiro Ogawa drives the adoption of advanced manufacturing technologies across the region. The President, Kbi Biopharma (Japan) coordinates with the global executive team to ensure that regional operations align with the overarching corporate strategy. Through the development of local talent and infrastructure, the President, Kbi Biopharma (Japan) strengthens the presence of the company in the Asian market. Ultimately, the President, Kbi Biopharma (Japan) accelerates the delivery of innovative medicines by bridging global capabilities with regional market needs.

    Debra Bruneau - Chief People Officer

    Debra Bruneau, the Chief People Officer at KBI Biopharma, directs the human capital strategy, talent acquisition, and organizational culture initiatives. Overseeing the development of a high-performance workforce, the Chief People Officer ensures that the company attracts and retains the scientific expertise necessary for complex biologics manufacturing. This leadership role involves designing programs that foster professional growth and align employee contributions with the core mission of the organization. By cultivating an environment of innovation and collaboration, Debra Bruneau drives engagement across all global teams. The Chief People Officer works closely with leadership to build a resilient organizational structure capable of adapting to the fast-paced demands of the life sciences industry. Through the implementation of strategic workforce planning, the Chief People Officer supports the operational scale of the business. Ultimately, the Chief People Officer ensures that the human element of the company remains a primary driver of success and scientific advancement.

    Frequently Asked Questions Regarding KBI Biopharma Top Executives and Leadership Team

    Who leads KBI Biopharma?
    KBI Biopharma is led by Lorraine Russ (Chief Executive Officer), along with executives such as Katherine Wolf (Chief Financial Officer) and Peter Carbone (Chief Operating Officer).
    Who is part of KBI Biopharma’s executive team?
    The executive team of KBI Biopharma includes leaders such as Lorraine Russ (Chief Executive Officer), Katherine Wolf (Chief Financial Officer), Peter Carbone (Chief Operating Officer) and other senior executives.
    How many executives does KBI Biopharma have?
    KBI Biopharma has 5 executives leading key business areas.
    What roles are included in KBI Biopharma’s leadership team?
    The leadership team of KBI Biopharma includes roles such as Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, President, Kbi Biopharma (Japan), Chief People Officer.